Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 30905548)

  • 1. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Gbolahan O; Hashemi-Sadraei N; O'Neil B
    J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
    Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
    Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
    Cheung PF; Lutz M; Siveke JT
    Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.